NUGALVIQ

Serial Number 97072078
606

Registration Progress

Application Filed
Oct 13, 2021
Under Examination
Oct 18, 2022
Approved for Publication
Aug 23, 2022
Published for Opposition
Aug 23, 2022
Registered

Attorney Assistance

Abandonment Notice E-Mailed - No Use Statement Filed
Due: Jan 24, 2026 19 days
Revival assistance for abandoned trademark

Trademark Image

NUGALVIQ

Basic Information

Serial Number
97072078
Filing Date
October 13, 2021
Published for Opposition
August 23, 2022
Abandonment Date
November 24, 2025
Drawing Code
3

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Nov 24, 2025
Classes
005

Rights Holder

Applied Therapeutics, Inc.

03
Address
545 Fifth Avenue, Suite 1400
New York, NY 10017

Ownership History

Applied Therapeutics, Inc.

Original Applicant
03
New York, NY

Applied Therapeutics, Inc.

Owner at Publication
03
New York, NY

Legal Representation

Attorney
Anna Kurian Shaw

USPTO Deadlines

Next Deadline
19 days remaining
Abandonment Notice E-Mailed - No Use Statement Filed
Due Date
January 24, 2026

Application History

39 events
Date Code Type Description Documents
Nov 24, 2025 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Nov 24, 2025 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Nov 24, 2025 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Nov 24, 2025 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Jul 10, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Jul 10, 2025 EX5G S SOU EXTENSION 5 GRANTED Loading...
Mar 18, 2025 EXT5 S SOU EXTENSION 5 FILED Loading...
Jul 10, 2025 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Mar 18, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 7, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Oct 7, 2024 EX4G S SOU EXTENSION 4 GRANTED Loading...
Oct 7, 2024 EXT4 S SOU EXTENSION 4 FILED Loading...
Oct 7, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 23, 2024 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 22, 2024 EX3G S SOU EXTENSION 3 GRANTED Loading...
Mar 22, 2024 EXT3 S SOU EXTENSION 3 FILED Loading...
Mar 22, 2024 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Sep 21, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 19, 2023 EX2G S SOU EXTENSION 2 GRANTED Loading...
Sep 19, 2023 EXT2 S SOU EXTENSION 2 FILED Loading...
Sep 19, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 14, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 10, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Mar 10, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Mar 10, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Oct 18, 2022 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Sep 12, 2022 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Sep 12, 2022 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Sep 12, 2022 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Aug 23, 2022 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 23, 2022 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 3, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jul 19, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 19, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 18, 2021 TAEA I TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED Loading...
Oct 18, 2021 PARI I TEAS VOLUNTARY AMENDMENT RECEIVED Loading...
Nov 4, 2021 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED Loading...
Nov 3, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 16, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for treatment of rare orphan diseases; Pharmaceutical preparations for treatment of diseases that impact sugar and glucose metabolism; Pharmaceutical preparations for inhibiting aldose reductase; Pharmaceutical preparations for treatment of galactosemia, sorbitol dehydrogenase (SORD) deficiency and PMM2-congenital disorder of glycosylation (PMM2-CDG)

Additional Information

Design Mark
The mark consists of three curved vertical lines consisting of dots of graduated sizes, with the word "NUGALVIQ" to the right of the design.

Classification

International Classes
005